Skip to content
Our reporters bring you news and highlights from BIO’s in-person and virtual events.
The pace of biotech investment has slowed recently, harming development at the small, new companies that are driving innovation. “Coming down from the heyday […]
BIO webinar will advise biotech on weathering the slowing investor market Read More »
With the partnering system to arrange face-to-face meetings at the BIO International Convention filling up at a record pace, anyone who wants to do
BIO International Convention partnering is moving at a record pace Read More »
The Council of State Bioscience Associations (CSBA), a coalition of state-based bioscience trade associations convened by the Biotechnology Innovation Organization (BIO), joined forces in
CSBA hits Capitol Hill for face time with lawmakers Read More »
When it comes to long COVID, health care providers and the biotech industry must be aware of what is already known, but we still
BIO’s long COVID webinar furthers search for biotech solutions Read More »
While research into long COVID-19 is offering clues to causes and potential targets for treatment, defeating this debilitating condition, which impacts millions, requires a
BIO’s online conference invites biotech to fight long COVID Read More »
Eleven years after the first CRISPR patent was filed, we’re anticipating what could be the first approval of a gene therapy based on CRISPR:
‘How do you price a cure?’ and other questions about the CRISPR era Read More »
The number of new pain drugs in the development pipeline has slowed to a trickle and investment in addiction drugs is low, challenges addressed
‘All hands on deck’ needed to address U.S. pain and addiction innovation Read More »
The Inflation Reduction Act’s drug price controls have been a hot topic during the BIO CEO and Investor Conference—and one that has hampered an
We’re already seeing the impact of drug price controls, say biotech CEOs Read More »
“I think we’re in a very exciting time in healthcare and biotech,” said Steven Ladd, Director of Business Development and Acquisitions at AbbVie. “It’s
China-U.S. biotech ventures are where collaboration meets competition Read More »
The narrative is that it’s a bad market for biotech, but CEOs and investors told a packed house at the 2023 BIO CEO and
Are SPACs dead? – and other questions about the biotech market outlook Read More »
